AU2017270221A1 - Combination therapies with farnesoid X receptor (FXR) modulators - Google Patents
Combination therapies with farnesoid X receptor (FXR) modulators Download PDFInfo
- Publication number
- AU2017270221A1 AU2017270221A1 AU2017270221A AU2017270221A AU2017270221A1 AU 2017270221 A1 AU2017270221 A1 AU 2017270221A1 AU 2017270221 A AU2017270221 A AU 2017270221A AU 2017270221 A AU2017270221 A AU 2017270221A AU 2017270221 A1 AU2017270221 A1 AU 2017270221A1
- Authority
- AU
- Australia
- Prior art keywords
- optionally substituted
- heteroaryl
- aryl
- group
- hydrogen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 CC*C(N(*)C(*)(*)C1(*)*)=C(C)c2c1c1nnccc1[n]2C Chemical compound CC*C(N(*)C(*)(*)C1(*)*)=C(C)c2c1c1nnccc1[n]2C 0.000 description 7
- PZXOLNODCZLMQO-UHFFFAOYSA-N CC(C)OC(C1=CNCC(C)(C)c2c1[nH]c(nc1)c2cc1Cl)=O Chemical compound CC(C)OC(C1=CNCC(C)(C)c2c1[nH]c(nc1)c2cc1Cl)=O PZXOLNODCZLMQO-UHFFFAOYSA-N 0.000 description 1
- RGCCKSLMWUJIMS-UHFFFAOYSA-N CCOCC(c([nH]1)c(C(C)(C)C2)[n]3c1cc(C)c3)=CN2C(OC(C)(C)C)=O Chemical compound CCOCC(c([nH]1)c(C(C)(C)C2)[n]3c1cc(C)c3)=CN2C(OC(C)(C)C)=O RGCCKSLMWUJIMS-UHFFFAOYSA-N 0.000 description 1
- RPQWXGVZELKOEU-UHFFFAOYSA-N O=C(c(cc1F)ccc1F)Cl Chemical compound O=C(c(cc1F)ccc1F)Cl RPQWXGVZELKOEU-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Gastroenterology & Hepatology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662341487P | 2016-05-25 | 2016-05-25 | |
| US201662341482P | 2016-05-25 | 2016-05-25 | |
| US62/341,482 | 2016-05-25 | ||
| US62/341,487 | 2016-05-25 | ||
| PCT/US2017/034564 WO2017205684A1 (en) | 2016-05-25 | 2017-05-25 | Combination therapies with farnesoid x receptor (fxr) modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2017270221A1 true AU2017270221A1 (en) | 2018-12-20 |
Family
ID=60412964
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2017270221A Abandoned AU2017270221A1 (en) | 2016-05-25 | 2017-05-25 | Combination therapies with farnesoid X receptor (FXR) modulators |
Country Status (13)
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112019025228A2 (pt) * | 2017-06-02 | 2020-06-23 | Akarna Therapeutics, Ltd. | Compostos bicíclicos fundidos |
| US11524029B2 (en) | 2018-08-13 | 2022-12-13 | Viscera Labs, Inc. | Therapeutic composition and methods |
| US11590161B2 (en) | 2018-08-13 | 2023-02-28 | Viscera Labs, Inc. | Therapeutic composition and methods |
| JP2022514731A (ja) * | 2018-08-14 | 2022-02-15 | アヴォリント | 原発性硬化性胆管炎の処置方法 |
| WO2020081766A1 (en) * | 2018-10-18 | 2020-04-23 | Avolynt | Use of sglt2 inhibitors to treat primary sclerosing cholangitis |
| CN121081472A (zh) | 2018-12-13 | 2025-12-09 | 拓臻股份有限公司 | 一种THRβ受体激动剂化合物及其制备方法和用途 |
| CN111825653A (zh) * | 2019-04-19 | 2020-10-27 | 安道麦马克西姆有限公司 | 取代吡唑类化合物的制备及其作为邻氨基苯甲酰胺前体的用途 |
| CA3154488A1 (en) | 2019-08-23 | 2021-03-04 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| CA3154391A1 (en) | 2019-09-12 | 2021-03-18 | Terns Pharmaceuticals, Inc. | Thyroid hormone receptor beta agonist compounds |
| EP4061357A4 (en) * | 2019-11-22 | 2024-01-10 | Avolynt | Use of sglt2 inhibitors to treat primary billiary cholangitis |
| IL296100A (en) * | 2020-03-11 | 2022-11-01 | Dong A St Co Ltd | A medicinal preparation for the prevention or treatment of non-alcoholic steatohepatitis |
| US11478533B2 (en) | 2020-04-27 | 2022-10-25 | Novo Nordisk A/S | Semaglutide for use in medicine |
| US20220034871A1 (en) * | 2020-07-31 | 2022-02-03 | Daiichi Sankyo Company, Limited | Methods for administering pexidartinib |
| PE20231096A1 (es) | 2020-08-25 | 2023-07-18 | Lilly Co Eli | Polimorfos de un inhibidor de ssao |
| US20240319210A1 (en) * | 2020-12-18 | 2024-09-26 | Human Metabolomics Institute, Inc. | Application of neonatal biliary atresia biomarker and detection method for same |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005009387A2 (en) * | 2003-07-23 | 2005-02-03 | X-Ceptor Therapeutics Inc. | Azepine derivatives as pharmaceutical agents |
| ATE526318T1 (de) * | 2005-12-19 | 2011-10-15 | Glaxosmithkline Llc | Farnesoid-x-rezeptor-agonisten |
| EP4137137A1 (en) * | 2010-05-26 | 2023-02-22 | Satiogen Pharmaceuticals, Inc. | Bile acid recycling inhibitors and satiogens for treatment of diabetes, obesity, and inflammatory gastrointestinal conditions |
| AU2015314830B2 (en) * | 2014-09-12 | 2021-01-07 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| CA2968434A1 (en) * | 2014-11-21 | 2016-05-26 | Akarna Therapeutics, Ltd. | Fused bicyclic compounds for the treatment of disease |
| RU2021107054A (ru) * | 2015-03-26 | 2021-03-31 | Акарна Терапьютикс, Лтд. | Конденсированные бициклические соединения для лечения заболевания |
-
2017
- 2017-05-25 MX MX2018014024A patent/MX2018014024A/es unknown
- 2017-05-25 WO PCT/US2017/034564 patent/WO2017205684A1/en not_active Ceased
- 2017-05-25 RU RU2018145776A patent/RU2018145776A/ru not_active Application Discontinuation
- 2017-05-25 BR BR112018073460A patent/BR112018073460A2/pt not_active Application Discontinuation
- 2017-05-25 JP JP2018562106A patent/JP2019517478A/ja active Pending
- 2017-05-25 KR KR1020187037471A patent/KR20190040936A/ko not_active Ceased
- 2017-05-25 US US16/303,741 patent/US20200397798A1/en not_active Abandoned
- 2017-05-25 AU AU2017270221A patent/AU2017270221A1/en not_active Abandoned
- 2017-05-25 CA CA3025007A patent/CA3025007A1/en not_active Abandoned
- 2017-05-25 SG SG11201810290WA patent/SG11201810290WA/en unknown
- 2017-05-25 CN CN201780045766.3A patent/CN109843298A/zh active Pending
- 2017-05-25 EP EP17803627.3A patent/EP3463373A4/en not_active Withdrawn
- 2017-05-25 SG SG10202011660RA patent/SG10202011660RA/en unknown
-
2018
- 2018-11-21 IL IL263179A patent/IL263179A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018014024A (es) | 2019-08-29 |
| BR112018073460A2 (pt) | 2019-07-09 |
| EP3463373A4 (en) | 2020-04-22 |
| WO2017205684A1 (en) | 2017-11-30 |
| CN109843298A (zh) | 2019-06-04 |
| SG10202011660RA (en) | 2020-12-30 |
| JP2019517478A (ja) | 2019-06-24 |
| KR20190040936A (ko) | 2019-04-19 |
| EP3463373A1 (en) | 2019-04-10 |
| RU2018145776A3 (cg-RX-API-DMAC10.html) | 2021-03-01 |
| CA3025007A1 (en) | 2017-11-30 |
| RU2018145776A (ru) | 2020-06-26 |
| US20200397798A1 (en) | 2020-12-24 |
| IL263179A (en) | 2018-12-31 |
| SG11201810290WA (en) | 2018-12-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2017205684A1 (en) | Combination therapies with farnesoid x receptor (fxr) modulators | |
| JP5411141B2 (ja) | 細胞内カルシウムを調節する化合物 | |
| US8552041B2 (en) | Therapeutic approaches for treating alzheimer disease and related disorders through a modulation of cell stress response | |
| TW202134221A (zh) | 苯并噻二氮呯化合物及其作為膽酸調節劑之用途 | |
| CA3198216A1 (en) | Benzothia(di)azepine compounds and their use as bile acid modulators | |
| US12396989B2 (en) | Nicorandil derivatives | |
| Zhao et al. | Targeting the GPR119/incretin axis: a promising new therapy for metabolic-associated fatty liver disease | |
| Zhao et al. | Puerarin alleviates coronary heart disease via suppressing inflammation in a rat model | |
| CN108721599A (zh) | 使用htcp抑制剂的疗法 | |
| KR20190062501A (ko) | 섬유증, 간경화 질환 또는 질병을 치료 또는 예방하기 위한 fxr 작용제를 포함하는 조합 조성물 | |
| AU2017328135A1 (en) | Novel regimes of FXR agonists | |
| CA3181902A1 (en) | Methods for treating or preventing chronic kidney disease | |
| JP2018516275A (ja) | ナフトキノン系化合物を含む、膵炎を治療又は予防する組成物 | |
| RU2727142C2 (ru) | Бисамидное производное дикарбоновой кислоты в качестве средства, стимулирующего регенерацию тканей и восстановление сниженных функций тканей | |
| KR101418161B1 (ko) | 네퍼린을 유효성분으로 포함하는 간암 예방 또는 치료용 약제학적 조성물 | |
| CN114555577A (zh) | 用于治疗门静脉炎症和纤维化的噻吩衍生物 | |
| JP2023538659A (ja) | Olig2阻害剤を用いる併用療法 | |
| KR100639163B1 (ko) | 다약제내성 억제 효과를 갖는 퀴놀린 유도체 및 이의 약제학적 조성물 | |
| KR20260049797A (ko) | 경도 인지 장애 치료를 위한 병용 요법의 치료제 조성물 및 사용 방법 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK5 | Application lapsed section 142(2)(e) - patent request and compl. specification not accepted |